New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePE-22-28 vs MGF (Mechano Growth Factor)

PE-22-28 vs MGF (Mechano Growth Factor)

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
PE-22-28
Anabolic & IGF
MGF (Mechano Growth Factor)
Summary
PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Half-Life
Relatively short; CNS effects may persist due to neurogenic mechanisms
Native MGF: minutes. PEG-MGF: ~3 days
Admin Route
SubQ, Intranasal
SubQ, IM
Research
Typical Dose
200–400 mcg
200–400 mcg
Frequency
Once daily
1–2 times per week
Key Benefits
  • Rapid-onset antidepressant effects (within 24 hours)
  • Promotes hippocampal neurogenesis
  • Improves cognitive performance and memory
  • Reduces anxiety and depressive behavior
  • Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
  • May help treatment-resistant depression
  • Neuroprotective effects
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
Side Effects
  • Generally well tolerated in animal models
  • Limited human data available
  • Possible mild headache or transient mood changes at initiation
  • Injection site reactions (SC)
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
Stacks With